ABBV vs PFE: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and Pfizer Inc. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-05.
AbbVie Inc. Β· Healthcare
$197.69
+6.3% upside to fair value
Grade C High Quality
VS
Pfizer Inc. Β· Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value (+28.6%). PFE trades at a lower forward P/E (19.3x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric ABBV PFE
Current Price $197.69 $26.33
Fair Value Estimate $210.22 $33.85
Upside to Fair Value +6.3% +28.6%
Market Cap $349.7B $149.8B
Forward P/E 83.3x 19.3x
EV / EBITDA 23.4x 12.9x
Price / Sales 5.7x 2.4x
Price / FCF 18.7x 16.5x
Revenue Growth YoY +10.0% -1.2%
Gross Margin 70.2% 70.3%
Operating Margin 26.7% 24.7%
Return on Equity -361.6% 8.7%
Dividend Yield 0% 0%
FCF Yield 5.35% 6.06%
Analyst Consensus Strong Buy Hold
Investment Thesis
ABBV β€” AbbVie Inc.
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
PFE β€” Pfizer Inc.
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
Metric ABBV PFE
Zone Low $157.66 $25.39
Zone High $178.69 $28.77
In Buy Zone? No Yes
← ABBV Research    PFE Research β†’    All Research